



**DATE PRESENTING CLINICAL SIGNS**

3.3.26 History: Recheck echo.  
Pertinent abnormal PE/Chem/CBC/UA Results: Renal values stable

**PATIENT**

Rosita Hylton

-Current medications: Pimobendan 1.25mg PO BID since 8/12/25, Frusemide 4 mg PO BID since 8/26/25  
-Sedation used: Not required to complete full diagnostic ultrasound.  
-Pertinent previous ultrasound results (8/21/25 MML): CVD severe, stage C. Severe MR, severe LAE, mild LVE, mild TR, mild PH, mild RHE. Scant PCE at that time. LA: 2.4, LV: 3.0, TR: 3.3.  
-STAT: Not requested.

**SPECIES**

Canine

**ECHOCARDIOGRAM FINDINGS**

**BREED**

Chihuahua

**SEX**

FS

**AGE**

8.11.17

2D, m-mode, color flow and doppler imaging is available. The mitral valve is diffusely thickened with prolapse into the left atrial lumen. There is severe eccentric mitral regurgitation present. The MR velocity is normal. There is severe left atrial enlargement. There is mild left ventricular dilation. Left ventricular systolic function is hyperdynamic. Mild right atrial and ventricular dilation (subjective). Mild thickening of the tricuspid valve with mild TR. Velocity consistent with early pulmonary hypertension. The aortic valve appears trileaflet with normal mobility. No significant AI. There is normal systolic flow velocity across the aortic valve. The main pulmonary artery is normal in diameter. The pulmonic valve is normal in appearance. Flow through the RVOT/PV is normal in velocity. Trace PI. No pericardial or pleural effusion or cardiac masses are seen.

**WEIGHT**

9lbs

**CARDIAC CHART**

**INTERPRETED BY**

Maggie Machen Lamy,  
DVM, DACVIM  
(Cardiology)

CANINE CARDIAC PARAMETERS	MR VMAX (m/s)	TR VMAX (m/s)	LA/AO (Boon method)	LA/AO (Heart Base; Swe)	FS (%)	EF (%)	EPSS (cm)
<b>NORMAL PARAMETER</b>	4.5-5.5	<2.7	1.3	<1.6	28-40	40-100	<0.6
<b>PATIENT</b>	5.8	3.1	NM	2.2	46	79	NM
CANINE CARDIAC PARAMETERS	HR (BPM)	AV VMAX (m/s)	PV MAX (m/s)	BODY WEIGHT (kg)	LA 2D short axis Base view (cm)	LVIDd Avg; 2D and m-mode short axis (cm)	LVIDs Avg; 2D and m-mode short axis (cm)
<b>NORMAL PARAMETER</b>	50-100	0.7-1.7	0.7-1.6	BELOW	BELOW	BELOW	BELOW
<b>PATIENT</b>	150	0.9	1.3	4.1	2.2	3.3	1.8
*Normal chamber parameters expressed as a mean value (SD)				3	1.27 (5.3)	2.46 (2.46)	1.36 (5.5)
<b>BODY WEIGHT DEPENDENT PARAMETERS</b>				5	1.40 (4.5)	2.74 (5.2)	1.60 (4.7)
<i>*Note: All measurements based upon multi-modal images and methods. An average value is reported.</i>				10	1.50 (3.8)	3.27 (3.5)	2.06 (3.1)
				15	1.83 (2.0)	3.71 (2.4)	2.43 (2.1)
				20	2.02 (1.9)	4.14 (2.2)	2.80 (2.0)
				25	2.18 (2.4)	4.48 (2.9)	3.10 (2.5)
				30	2.33 (3.3)	4.83 (3.9)	3.39 (3.4)
				35	2.48 (4.3)	5.17 (5.0)	3.69 (4.5)
				40	2.62 (5.2)	5.48 (6.1)	3.96 (5.4)
				50	2.88 (7.1)	6.07 (8.3)	4.46 (7.4)

**HOSPITAL NAME**

Warm & Fuzzy VC

**REFERRING VET**

Dr. Williams

**INVOICE**

47075

Adapted from June Boon, Veterinary Echocardiography, 1998  
Rishniw M and Hollis NE, J Vet Intern Med 2000; 14:429-435  
Hansson et al, Vet Rad and Ultrasound 2002  
Bonagura et al. Echocardiography: principles of interpretation, Vet Clin North Am 15:1177, 1995

### **INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

Compared to the prior study, findings are similar. Severe MR and mild TR are unchanged with stable yet severely dilated LA and LV dimensions. Mild pulmonary hypertension is similar to previous, and no additional issues have developed.

Given these findings, full cardiac support should be continued going forward. The average survival of canine patients with active pulmonary edema is 8-9 months on medications; however, they generally are able to maintain a good quality of life for that period. Patient will always be at risk for recurrent CHF, development of arrhythmias/LA tear, syncope and/or sudden death in the future. Monitoring of renal values is recommended lifelong.

Omega fatty acid supplementation and mild salt restriction may also be of some long-term benefit. Monitor for development of a worsening cough, labored breathing, exercise intolerance or collapse episodes.

Elective anesthesia is not advised, as there is high risk for complication.


### **PLAN**

Continue Pimobendan 0.3mg/kg PO q12h. Continue Lasix 1-2mg/kg PO q12h. Pending BP >130mmHg, institute ACE-I 0.5mg/kg PO q12h. Institute Spironolactone 1-2mg/kg PO q12h.

A renal panel and BP are recommended every 3-4 months on diuretics to ensure tolerance of medications.

A recheck echocardiogram is recommended in 6 months to screen for progression, sooner if clinical signs arise/persist.

### **IMAGES**



**The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.**

Thank you for this referral. This report was generated using transcription software, and minor dictation errors may be present. If the clinical or image interpretation does not parallel your findings or if I can be of

any further assistance, please contact me.

**Maggie Machen Lamy, DVM**  
**Diplomate of the American College of Veterinary Internal Medicine (Cardiology)**  
**info@sonopath.com**